Assessing Commerce.com (CMRC) Valuation Following Embedded Payments Partnership with Fortis

Commerce.com (CMRC) is drawing fresh attention after announcing a strategic partnership with Fortis to integrate advanced embedded payments technology for BigCommerce customers. This move stands out, as it directly targets the operational headaches many online sellers face by streamlining checkout, simplifying reconciliation, and enabling faster access to funds. For investors weighing what to do next, the tangible benefits of this collaboration could signal the start of a new direction for the company, especially as eCommerce players look for scalable and unified solutions.

Despite this promising integration, Commerce.com’s share price has moved sideways in the past year, reflecting skepticism about its slower revenue growth compared to the broader industry. Shares are roughly 11% below where they started last year and the stock has yet to regain positive momentum, even with a modest 7% rise over the past month. This ambivalent pattern stands in contrast to broader expectations for high growth in software and eCommerce, raising questions about how much future upside is already factored in.

With the Fortis partnership in play and expectations reset, does recent price action offer a genuine buying opportunity, or has the market already accounted for any growth Commerce.com might achieve?

Advertisement

Most Popular Narrative: 31.3% Undervalued

The prevailing narrative sees Commerce.com as significantly undervalued, with its current share price trading well below consensus fair value estimates informed by growth and profitability assumptions.

The company has recruited top leaders with extensive experience in SaaS and commerce. This is expected to enhance its strategic execution and potentially increase revenue growth. The reorganization of sales, marketing, strategic partnerships, and customer success is anticipated to improve sales efficiency and effectiveness. These changes may drive revenue growth while maintaining a focus on profitable operations.

Want to know why industry insiders think this company is poised for a sharp rerating? The widely followed narrative projects bold improvements in margins and outsized growth assumptions. What big improvements must materialize for this stock to meet such a high bar? The full story behind these bullish calculations might surprise you.

Result: Fair Value of $7.56 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, if Commerce.com fails to hit revenue targets or if restructuring drags on, the anticipated turnaround could stall and put further pressure on shares.

Find out about the key risks to this Commerce.com narrative.

Another View: Discounted Cash Flow Stands Out

While market watchers focus on valuation based on sales, our DCF model looks deeper at future cash flows and also finds the shares undervalued. When two methods align like this, is the market missing something?

Look into how the SWS DCF model arrives at its fair value.
CMRC Discounted Cash Flow as at Sep 2025
CMRC Discounted Cash Flow as at Sep 2025
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Commerce.com for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Commerce.com Narrative

If you think the story looks different or prefer doing your own analysis, it takes just a few minutes to chart your own view and share a fresh perspective. Do it your way

A great starting point for your Commerce.com research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Smart investors never settle for average opportunities. Head to Simply Wall Street’s tools and target the next wave of winners before the crowd catches on. Some of tomorrow’s best-performing stocks could be hiding in plain sight.

  • Tap into excitement around automation by spotting opportunities in companies poised to benefit from the rise of AI penny stocks and their transformative impact.
  • Unlock the next generation of income streams and steady payouts with our selection of dividend stocks with yields > 3% that deliver attractive yield potential.
  • Uncover overlooked gems the market has mispriced by zeroing in on undervalued stocks based on cash flows ready for a possible rebound.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGM:CMRC

Commerce.com

Provides artificial intelligence-driven commerce ecosystem in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally.

Undervalued with excellent balance sheet.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
67 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
185 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
71 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0